12.00- 12.10  

prof. MACIEJ MAŁECKI 

Jagiellonian University, Kraków, Poland
 
prof.  ARTUR JURCZYSZYN

Jagiellonian University, Kraków, Poland

opening the international  conference

Chairmen of the Session nr I 

prof. Wiesław Jędrzejczak 
prof. Aleksander Skotnicki
dr Wojciech Legieć 

12.10 - 12.30

prof. GÖSTA GAHRTON

Karolinska Institut, Sweden

 “History of treatment of multiple myeloma”  

12.30-12.40

 discussion

12.40 - 13.00

prof. HERMANN EINSELE

University Hospital of Wurzburg, Germany

  “CAR-T Cells in myeloma: current practice and future developments”

13.00-13.10

discussion

13.10 - 13.30

prof. MORIE A.GERTZ

Mayo Clinic, USA

13.30-13.40

discussion

13.40 - 14.00

prof. DAVID H. VESOLE

Hackensack University Medical Center, New Jersey Medical School,  rutgers University, New Jersey, USA

 “Bispecific T-cell engager therapy for multiple  myeloma”  

14.00-14.15

discussion

14.15 - 15.00

COFFE BREAK 

Chairmen of the Session nr II

prof. Tomasz Sacha
dr hab. Grzegorz Charliński
dr Paweł Steckiewicz

15.00 -15.20

prof.  GHULAM REHMAN MOHYUDDIN

Division of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

 “Quality of life in multiple myeloma in 2026”

15.20-15.30

discussion

15.30 -15.50

prof.  ATTAYA SUVANNASANKHA

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, USA

“Advances in systemic AL amyloidosis”

15.50-16.00

discussion

16.00 – 16.20 

prof. JOSHUA RICHTER

Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

 “Practical aspects of immunotherapy in multiple myeloma”
 

16.20-16.30

discussion

16.30 - 16.50

prof. RAHUL BANERJEE

Fred Hutchinson Cancer Center, Seattle, USA           

"How I define and treat high - risk multiple myeloma”

prof. LARYSA SANCHEZ

Departament of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA Washington, Seattle, USA   

prof.  ARTUR JURCZYSZYN

Jagiellonian University, Kraków, Poland